Effects of the Glucocorticoid Antagonist, Mifepristone, on Glucose Intolerance in Obese and Overweight Individuals
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Mifepristone (Primary)
- Indications Metabolic syndrome; Obesity
- Focus Therapeutic Use
- 04 Feb 2021 New trial record
- 28 Jan 2021 Results published in the Journal of Clinical Endocrinology and Metabolism